Aptuit acquires Kuecept

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototyping and formulation development services

Pharmaceutical service company Aptuit has acquired Kuecept to help meet demand for specialist drug pre-formulation, formulation prototyping and formulation development services.

No financial details have been released.

London, UK-based Kuecept offers technical expertise in CRO services supporting preclinical drug development. The firm provides pre-formulation testing, preclinical dose-vehicle screening and formulation development.

These services are complemented by a range of drug-delivery technologies. The firm has extensive experience in respiratory, parenteral and oral formulation development for insoluble compounds. Formulation rescue consultancy helps companies move APIs through IND/CTA enabling safety assessment.

Aptuit CEO Jonathan Goldman said the acquisition 'enhances our scientific expertise and capabilities in the pre-formulation development space'.

It also allows Aptuit to improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory based Drug Product Development.

Goldman added: 'Kuecept scientists are skilled in using small milligram quantities of API in the critical de-risking phase of late stage discovery. Technologies such as hot melt extrusion, spray drying, wet and dry micronisation and cutting edge microsphere chemistry are all routinely performed on very small amounts of API to develop robust and practical formulations. Kuecept's knowledge also further enhances our candidate to IND/CTA solution (INDiGO). We expect our customers to benefit from improved solubility solutions, reduced drug attrition and associated reductions in time and development costs.'

Mark Saunders, CEO and founder of Kuecept added: 'Through this acquisition, our customers can now combine our capabilities with Aptuit's full suite of integrated drug development solutions to facilitate the transition of new drugs through preclinical evaluation to clinical manufacture. Kuecept and Aptuit share a common culture and commitment to scientific excellence, making this a very good fit.'

Companies